To Enhance Cognition in Late Life Depression Using Transcranial Direct Current Stimulation
Launched by CENTRE FOR ADDICTION AND MENTAL HEALTH · Aug 7, 2014
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
tDCS is a non-invasive brain stimulation method that utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. tDCS produces its effects through long lasting changes in neuroplasticity: in animal studies, tDCS results in long-term potentiation and brain-derived neurotrophic factor secretion; in human studies, tDCS results in potentiation of neurophysiologic markers of neuroplasticity. Consistent with these preclinical findings, tDCS to the temporoparietal cortex or left DLPFC im...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Women and men of any races or ethnicity
- • 2. Age 60 and above
- • 3. Major depressive disorder, single or recurrent per SCID DSM-IV criteria AND remission from that episode as defined by DSM IV-TR criteria for remission.
- • 4. Montgomery-Asberg Depression Rating Scale (MADRS) score less than 10.
- • 5. Ability to speak English fluently enough to complete all research assessments.
- • 6. Corrected visual ability to read newspaper headlines; hearing capacity to respond to a raised conversational voice
- • 7. Willingness and ability to provide consent
- Exclusion Criteria:
- • 1. DSM IV TR criteria for any dementia
- • 2. DSM IV TR criteria for life-time bipolar disorder, schizophrenia, schizoaffective disorder, or other psychotic disorders
- • 3. DSM IV TR criteria for any substance abuse or dependence within the past 6 months
- • 4. Presence of psychotic features or any other symptoms that would make the participant unable to participate in the study.
- • 5. Any medical contra-indications to tDCS.
- • 6. Electroconvulsive therapy in the last 6 months.
About Centre For Addiction And Mental Health
The Centre for Addiction and Mental Health (CAMH) is Canada’s leading mental health and addiction teaching hospital, dedicated to advancing research, clinical care, and education in the field of mental health. With a commitment to improving the lives of individuals affected by mental illness and addiction, CAMH conducts innovative clinical trials aimed at developing and evaluating new treatment approaches. The institution fosters a collaborative environment that brings together researchers, clinicians, and community partners to translate scientific findings into effective interventions, ensuring the highest standards of care and support for patients. Through its robust research initiatives, CAMH strives to enhance understanding of mental health disorders and promote evidence-based practices in the treatment of addiction and mental health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Tarek K Rajji, MD
Principal Investigator
Center for Addiction and Mental Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials